

Facsimile Cover Sheet

MEDLEN & CARROLL, LLP

TO: Examiner Susan Ungar
Group No.: 1642
US PTO
Tel: (703) 305-2181
Fax: (703) 746-3142

FROM: Maha Hamdan
Medlen & Carroll, LLP
101 Howard Street, Suite 350
San Francisco, CA 94105
Tel: (510) 237-8552; (415) 904-6500
Fax: (510) 234-8696; (415) 904-6510

Date: July 15, 2002

Time: _____ AM / PM

Pages (including cover): _____

Client Code: UCSD-06555

The documents accompanying this facsimile transmission contain information from the law firm of MEDLEN & CARROLL, LLP which are confidential or privileged. The information is intended to be for the use of the individual or entity named on this cover sheet. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of the contents of this faxed information is prohibited. If you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the return of the original documents. Thank you.

Ms. Ungar:

This is further to my telephone message of today regarding Serial No. 09/307,223 to Dr. Judith Varner.

Enclosed is a copy of the Declaration by Dr. Virgil Woods, Jr. under 37 C.F.R. §1.132 and his curriculum vitae (total 15 pages) which was enclosed with our response mailed on 2/19/02, and which you indicated in the office action mailed on 5/21/02 that you did not receive.

I look forward to our interview of August 5, 2002 at 3:00 p.m. at the PTO (Crystal Mall One, 7th floor). Please do not hesitate to call me at 510-237-8552 if I may of further assistance.

Best regards,

Maha Hamdan

Maha A. Hamdan
Registration No. 43,655

13-15
22-29

PATENT

Attorney Docket No. UCSD-06555

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Judith A. Varner


Serial No.: 09/307,223

Filed: 05/07/99

Entitled: METHODS FOR DETECTING AND
INHIBITING ANGIOGENESIS

Group No.: 1642

Examiner: S. Ungar

DECLARATION OF DR. VIRGIL L. WOODS, JR.
UNDER 37 C.F.R. §1.132Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

1. I, Dr. Virgil L. Woods, am the subject of the attached Curriculum Vitae and author of the publications shown on the list attached thereto. On the basis of the information and facts contained in these documents, I submit that I have been, and am, practicing in the field of integrin biology and biochemistry, and am qualified to speak on the level of ordinary skill in these fields.

2. I have read and understand the above-identified patent application, and pending claims as amended in the Amendment And Response which was mailed to the Office on September 5, 2001.

3. Claim 2 recites an agent which "does not substantially interfere with the specific binding of a ligand to an integrin other than $\alpha 5 \beta 1$ integrin to its ligand."

PATENT
Attorney Docket No. UCSD-06555

4. The Specification teaches that "As discussed for anti- $\alpha 5\beta 1$ antibodies, a peptide that specifically binds $\alpha 5\beta 1$ can be useful in a method of the invention where the antibody binds to $\alpha 5\beta 1$ with at least about a two-fold greater specificity than it binds to another integrin, . . . is more useful if it has at least about a five-fold greater specificity for $\alpha 5\beta 1$, and is particularly useful if it has at least about a one order of magnitude greater specificity for $\alpha 5\beta 1$ than for an integrin such as $\alpha V\beta 3$."¹

Based on this teaching, it is my understanding that Claim 2's term "substantially" refers to the exemplary preferred mathematical ranges (*i.e.*, at least about two-fold, five-fold, and ten-fold) for binding of the ligand (as exemplified by a peptide or antibody) to $\alpha 5\beta 1$ integrin, as compared to binding of the ligand to another integrin. From this teaching, it is my understanding that Claim 2's recitation of an agent which "does not substantially interfere with the specific binding of a ligand to an integrin other than $\alpha 5\beta 1$ integrin" means that the agent's interference with the specific binding of $\alpha 5\beta 1$ integrin to a ligand is at least two-fold greater than the interference of the agent with the specific binding of another integrin to its cognate ligand.

5. Claims 80-86, 90-96, and 110-116 recite that the binding of an "agent" to $\alpha 5\beta 1$ integrin is at least two-fold, five-fold, or ten-fold greater than binding of the agent to an integrin other than $\alpha 5\beta 1$ integrin.

6. The Specification teaches that "As disclosed herein, antibody, peptide and nonpeptide small organic molecule antagonists of $\alpha 5\beta 1$ can interfere with the specific binding of $\alpha 5\beta 1$ integrin with its ligands, particularly fibronectin, in vascular tissue, and can reduce or inhibit angiogenesis (see Examples II, III and IV). Such molecules that interfere with the specific binding of $\alpha 5\beta 1$ with its ligands are referred to herein generally as '*agents*.'"²

The Specification also teaches that "The term '*antagonist*' is used herein to mean an *agent*, which can be an antibody, a peptide or a nonpeptide small organic molecule."³

¹ Specification, page 23, lines 5-14.

² (Emphasis added) Specification, page 18, lines 7-15.

³ (Emphasis added) Specification, page 19, lines 24-27.

PATENT
Attorney Docket No. UCSD-06555

Based on these teachings, it is my understanding that the term "agent" of Claims 80-86, 90-96, and 110-116 is exemplified by an antibody, peptide, and/or nonpeptide small organic molecule.

7. The Specification teaches that "As discussed for anti- $\alpha 5\beta 1$ antibodies, a peptide that specifically binds $\alpha 5\beta 1$ can be *useful* in a method of the invention where the antibody binds to $\alpha 5\beta 1$ with at least about two-fold greater specificity than it binds to another integrin, . . . is more useful if it has at least about a five-fold greater specificity for $\alpha 5\beta 1$, and is particularly useful if it has at least about a one order of magnitude greater specificity for $\alpha 5\beta 1$ than for an integrin such as $\alpha V\beta 3$."⁴

Based on this teaching, it is my understanding that one property which makes an antibody or a peptide "useful" as an antagonist of $\alpha 5\beta 1$ binding to its ligand(s) is that the antibody or peptide binds with at least about two-fold greater, at least about five-fold greater, or at least about ten-fold greater specificity for $\alpha 5\beta 1$ than for $\alpha V\beta 3$. From this understanding in combination with my further understanding that an antibody and peptide are examples of an "agent," (as explained in item 6, *supra*), it is my opinion that the inventor contemplated that this desirable property (*i.e.*, relative binding to $\alpha 5\beta 1$ as compared to $\alpha V\beta 3$) which makes the exemplary antibodies and peptides "useful" in the claimed methods, is also a desirable property that is contemplated for **any other type of agent**, including the third exemplary type of nonpeptide small organic molecule. In other words, the Specification conveys to me that the inventor contemplated that one desirable property of **any agent** that interferes with the specific binding of $\alpha 5\beta 1$ integrin to its ligand is that the agent (regardless of its type) binds with at least about a two-fold greater, at least about five-fold greater, or at least about ten-fold greater specificity for $\alpha 5\beta 1$ than for $\alpha V\beta 3$.

8. Claims 86, 96, and 116 recite that an agent which interferes with specific binding of the $\alpha 5\beta 1$ integrin to a ligand "does not interfere with the specific binding of a ligand to an integrin other than $\alpha 5\beta 1$ integrin."

⁴ (Emphasis added) Specification, page 23, lines 5-14.

PATENT
Attorney Docket No. UCSD-06555

9. The Specification teaches that "Particularly useful antibodies for performing a method of the invention are those that specifically bind to an $\alpha 5 \beta 1$ integrin. Such antibodies are particularly useful where they bind $\alpha 5 \beta 1$ with at least an order of magnitude greater affinity than they bind another integrin, for example, $\alpha V \beta 3$ or $\alpha V \beta 5$. An anti-fibronectin antibody also can be *useful* in a method of the invention, particularly an anti-fibronectin antibody that interferes with *binding* of fibronectin to $\alpha 5 \beta 1$ integrin, *but not to $\alpha V \beta 3$ or other integrin.*"⁵

Based on this teaching, it is my understanding that one desirable property which makes an antibody "useful" in the claimed methods is that the antibody does not interfere with the specific binding of a ligand (such as fibronectin) to an integrin other than $\alpha 5 \beta 1$. While this teaching refers to a desirable property of an antibody, it is nonetheless my opinion that this desirable property was contemplated by the inventor to apply to *any agent* because the Specification teaches that antibodies are an example of an agent (as explained *supra* in item 6).

10. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing therefrom.

Dated: 1/2/2002By: 

Dr. Virgil L. Woods

⁵ (Emphasis added) Specification, page 22, lines 15-19.

CURRICULUM VITAE

January 2, 2002

NAME: Virgil L. Woods, Jr., M.D.

SOCIAL SECURITY NO.: 563-70-6965

CURRENT POSITION: Associate Professor of Medicine & Orthopaedics
Division of Rheumatology
Department of Medicine
Department of Orthopaedics
University of California, San Diego

OFFICE ADDRESS: University of California, San Diego
Basic Science Building, Rm 5078
9500 Gilman Dr.
La Jolla, California 92093-0656

BUSINESS TELEPHONE: (619) 534-2180
FAX TELEPHONE: (619) 534-2606
EMAIL: vwoods@ucsd.edu

PERSONAL AND FAMILY:

BIRTH DATE: July 8, 1948

BIRTH PLACE: Oakland, California

MARITAL STATUS: Married, three children

EDUCATION:

1972 B.S., University of California, San Francisco, Major: Medical Sciences
1974 M.D., University of California, San Francisco, Major: Medicine
1979 B.A., University of California, San Diego, Major: Biochemistry

PROFESSIONAL EXPERIENCE:

1974 - 1975 Intern in Medicine, Barnes Hospital, St. Louis, Missouri
1975 - 1976 Resident in Medicine, Barnes Hospital, St. Louis, Missouri
1976 - 1979 Research Associate, Laboratory of Immunology, NIAID-NIH, Bethesda, MD
1979 - 1981 Rheumatology Fellow, University of California, San Diego
1981 - 1988 Assistant Professor of Medicine In Residence, University of California, San Diego
1988 - 1989 Associate Professor of Medicine in Residence, University of California, San Diego
1989 - 1992 Associate Professor of Medicine, University of California, San Diego
1992 - Present Associate Professor of Medicine and Orthopaedics, University of California, San Diego

MILITARY SERVICE:

July 1977 to U.S. Public Health Service
July 1979 Discharged with rank of Surgeon (Lt. Commander)

MEDICAL SPECIALTY BOARDS:

1978 American Board of Internal Medicine
1991 Subspecialty Boards in Rheumatology

FEDERAL GOVERNMENT PUBLIC ADVISORY COMMITTEES:
Grant Reviewer, Study Section for NIH NIAMD**MEMBERSHIP IN PROFESSIONAL SOCIETIES:**

Member, American College of Rheumatology
Member, Alpha Omega Alpha Medical Society
Member, American Society of Hematology
Member, American Heart Association, Council on Thrombosis
Member, FASEB

REVIEWER FOR:

Arthritis and Rheumatism
Blood
Journal of Biological Chemistry
Protein Science
Experimental Cell Research

BIBLIOGRAPHY

ARTICLES

1. Woods, VL Jr, DE Nitecki and JW Goodman. The capacity of bifunctional antigens to bridge antibody molecules and to mediate cell cooperation. *Immunochem* 12:379-382, 1975.
2. Wilder, RL, CC Yuen, B Subbarao, VL Woods Jr, CB Alexander, and RC Mage. Tritium (3H) radiolabeling of protein-A and antibody to high specific activity: application to cell surface antigen radioimmunoassays. *J Immunol Meth* 28 (3-4):255-256, 1979.
3. Finkelman, FD, VL Woods Jr, A Berning, and I Scher. Demonstration of mouse serum IgD. *J Immunol* 123(3):1253-1259, 1979.
4. Kessler, SW, VL Woods Jr, FD Finkelman, and I Scher. Membrane orientation and location of multiple and distinct allotypic determinants of mouse lymphocyte IgD. *J Immunol* 123(6):2772-2778, 1979.
5. Finkelman, FD, JJ Mond, VL Woods Jr, S Wilburn, A Berning, E Sehgal, and I Scher. Effects of anti-immunoglobulin antibodies on murine B-lymphocyte and humoral immune responses. *Immunol Rev* 52:55, 1980.
6. Finkelman, FD, VL Woods Jr, S Wilburn, JJ Mond, KE Stein, A Berning, and I Scher. Augmentation of in vitro humoral immune responses in the mouse by an antibody to IgD. *J Exp Med* 152(3):493-506, 1980.
7. Woods, VL Jr, FD Finkelman, I Scher, and WE Paul. IgD allotypic determinants. I. Determinants expressed on murine IgD of the a allotype. *J Immunol* 125(6):2699-2707, 1980.
8. Woods, VL Jr, I Scher, and WE Paul. IgD allotypic determinants. II. Determinants expressed on IgD of mice of the b, e, and o Igh-C haplotypes. *J Immunol* 125(6):2708-2712, 1980.
9. Laskov, R, J Kim, VL Woods Jr, P McKeever, and R Asofsky. Spontaneous B lymphoma in aged BALB/c mice predominantly express membrane IgM and IgD with lambda type light chain. *Eur J Immunol* 11:462-468, 1981.
10. Bluestein, HG, and VL Woods Jr. Antineuronal antibodies in systemic lupus erythematosus. *Arthritis Rheum* 25:773-778, 1982.
11. Woods, VL Jr, EH Oh, D Mason, and R McMillan. Autoantibodies against the platelet glycoprotein IIb/IIIa complex in patients with chronic ITP. *Blood* 63:368-375, 1984.
12. Woods, VL Jr, Y Kurata, RR Montgomery, P Tani, D Mason, EH Oh, and R McMillan. Autoantibodies against platelet glycoprotein Ib in patients with chronic immune thrombocytopenic purpura. *Blood* 64:156-160, 1984.

13. Anderson, MJ, VL Woods Jr, P Tani, JM Lindstrom, D Schmidt, and R McMillan. Autoantibodies to platelet glycoprotein IIb/IIIa and to the acetylcholine receptor in a patient with chronic idiopathic thrombocytopenic purpura and myasthenia gravis. *Ann Intern Med* 100:829-831, 1984.
14. Woods, VL Jr, and R McMillan. Platelet autoantigens in chronic ITP (Annotation). *Brit J Haematol* 57:1-4, 1984.
15. Plow, EF, RP McEver, BS Collier, VL Woods Jr, GA Marguerie, and MH Ginsberg. Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor and thrombospondin on thrombin-stimulated human platelets. *Blood* 66:724-727, 1985.
16. Pischel, KD, HG Bluestein, and VL Woods Jr. Very late activation antigens (VLA) are human leukocyte-neuronal crossreactive cell surface antigens. *J Exp Med* 164:393-406, 1986.
17. Courtois, G, JJ Ryckewaert, VL Woods, MH Ginsberg, EF Plow, and GA Marguerie. Expression of intracellular fibrinogen on the surface of stimulated platelets. *Eur J Biochem* 159:61-67, 1986.
18. Wencel-Drake, JD, EF Plow, TJ Kunicki, VL Woods Jr, DM Keller, and MH Ginsberg. Localization of internal pools of membrane glycoproteins involved in platelet adhesive responses. *Amer J Pathol* 124:324-334, 1986.
19. Bluestein, HG, KD Pischel, and VL Woods Jr. Immunopathogenesis of the neuropsychiatric manifestations of systemic lupus erythematosus. *Springer Semin Immunopathol* 9:237-249, 1986.
20. Woods, VL Jr, LE Wolff, and DM Keller. Resting platelets contain a substantial centrally located pool of glycoprotein IIb-IIIa complex which may be accessible to some but not other extracellular proteins. *J Biol Chem* 261:15242-15251, 1986.
21. Pischel, KD, ME Hemler, C Huang, HG Bluestein, and VL Woods Jr. Use of the monoclonal antibody 12F1 to characterize the differentiation antigen VLA-2. *J Immunol* 138:226-233, 1987.
22. Pischel, KD, SD Marlin, TA Springer, VL Woods Jr, and HG Bluestein. Polymorphism of lymphocyte function associated antigen-1, LFA-1 demonstrated by a lupus patient's alloantiserum. *J Clin Invest* 79:1607-1614, 1987.
23. Tsubakio, T, P Tani, VL Woods Jr, and R. McMillan. Autoantibodies against platelet GPIIb/IIIa in chronic ITP react with different epitopes. *Br J Haematol* 67:345, 1987.
24. McMillan, R, P Tani, F Millard, P Berchtold, L Renshaw, and VL Woods Jr. Platelet-associated and plasma anti-glycoprotein autoantibodies in chronic ITP. *Blood* 70:1040, 1987.
25. Pischel, KD, HG Bluestein, and VL Woods Jr. Platelet glycoproteins Ia, Ic, and IIa are physicochemically indistinguishable from the very late activation antigens adhesion-related proteins of lymphocytes and other cell types. *J Clin Invest* 81:505-513, 1988.
26. Santoro, SA, SM Rajpara, WD Staatz, and VL Woods, Jr. Isolation and characterization of a

- platelet surface collagen binding complex related to VLA-2. *Biochem Biophys Res Comm* 153:217-228, 1988.
27. Woods, VL Jr., KD Pischel, ED Avery, and HG Bluestein. Antigenic polymorphism of human very late activation protein-2 (platelet glycoprotein Ia-IIa). Platelet alloantigen Hca. *J Clin Invest* 83:979-985, 1989.
 28. Savage, B, C Hunter, LA Harker, VL Woods, Jr. and SR Hanson. Thrombin-induced increase in surface expression of epitopes on platelet membrane glycoprotein IIb/IIIa complex and GMP-140 is a function of platelet age. *Blood*, 74(3):1007-1014, 1989.
 29. Smith, JW, JG Kelton, P Horsewood, C Brown, A Giles, D Hunter, R Meyer, V Woods, and R Burrows. Platelet specific alloantigens (Zava/Zavb) on the platelet glycoprotein Ia/IIa complex. *Br J Haematol* 72:4, 1989.
 30. Schorer, AE, PG Duane, VL Woods, DE Niewoehner. Antiphospholipid antibodies inhibit phospholipase A2 activity. *J Lab Clin Med* 120:67-77, 1992.
 31. Gesink, DS, HO Pacheco, S Kuiper, D Amiel, WH Akeson, and VL Woods, Jr. Immunohistochemical localization of $\beta 1$ integrins in anterior cruciate and medial collateral ligaments of the human and rabbit. *J Ortho Res* 10:596-599, 1992.
 32. Berlin, OB, D Samid, R Donthineni-Rao, WH Akeson, D Amiel, VL Woods Jr. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of nude mice. *Cancer Research* 53:4890-4895, 1993.
 33. Woods, VL, Jr, PJ Schreck, DS Gesink, HO Pacheco, D Amiel, WH Akeson, and M Lotz. Integrin expression by human articular chondrocytes. *Arthritis Rheum* 37:537-544, 1994.
 34. Chen, PP, DA Carson, P Fischer, HH Handley, SJC Leu, R Mcmillan, W Novotny, T Olee, and VL Woods. Molecular genetics or human autoantibodies. *Pathol Biol*, 42(8):798-800, 1994.
 35. Schreck, PJ, LR Kitabayashi, D Amiel, WH Akeson, and VL Woods Jr. Integrin receptor display increases in the wounded rabbit medial collateral ligament but not in the anterior cruciate ligament. *J Orthop Res*, 13:174-183, 1995.
 36. Ruoslahti, E, M Pierschbacher, and VL Woods Jr. The $\alpha 5 \beta 1$ integrin in tumour suppression. *Bull. Inst Pasteur*, 92(4):242-247, 1995.
 37. Maemura, M, SK Akiyama, VL Woods, Jr, RB Dickson. Expression and ligand binding of $\alpha 2 \beta 1$ integrin on breast carcinoma cells. *Clin Exp Metastasis*, 13:223-235, 1995.
 38. AbiEzzi, SS, DS Gesink, PJ Schreck, D Amiel, WH Akeson, and VL Woods Jr. Increased expression of the $\beta 1$, $\alpha 5$, and αv integrin adhesion receptor subunits occur coincident with remodeling of stress-deprived rabbit anterior cruciate and medial collateral ligaments. *J Orthop Res*, 13:594-601, 1995.